Research Report Details

Author / Researcher : Global Markets Direct

Report Statistics

Number Of Pages/Tabs : 67

Number Of Charts : N/A

Published Date : 04/27/2016

Industries : Multiple

Countries : All

Quality Score : 5

Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us

Rosacea - Pipeline Review, H1 2016
Rosacea - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Rosacea - Pipeline Review, H1 2016’, provides an overview of the Rosacea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Rosacea - The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects - The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Rosacea Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Rosacea - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rosacea Overview 7
Therapeutics Development 8
Pipeline Products for Rosacea - Overview 8
Rosacea - Therapeutics under Development by Companies 9
Rosacea - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Rosacea - Products under Development by Companies 13
Rosacea - Companies Involved in Therapeutics Development 14
Allergan Plc 14
Amorepacific Corporation 15
Delenex Therapeutics AG 16
Foamix Pharmaceuticals Ltd. 17
Hovione FarmaCiencia SA 18
Merz Pharma GmbH & Co. KgaA 19
Promius Pharma, LLC 20
TWi Pharmaceuticals, Inc. 21
Valeant Pharmaceuticals International, Inc. 22
Rosacea - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
AC-701 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ACUD-1 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DLX-1008 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DMT-200 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DMT-210 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DMT-220 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
FMX-103 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
incobotulinumtoxin A - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
itraconazole - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
minocycline - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
omiganan pentahydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
oxymetazoline hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PAC-14028 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PDI-320 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
tetracycline MR - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Rosacea - Recent Pipeline Updates 51
Rosacea - Dormant Projects 57
Rosacea - Discontinued Products 59
Rosacea - Product Development Milestones 60
Featured News & Press Releases 60
Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 60
Apr 07, 2015: Dr. Reddy’s Laboratories and its subsidiary Promius Pharma announce the filing of NDA with the USFDA For DFD-09 60
Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 61
Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 61
Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 62
Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 63
Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 63
Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 64
Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 65
Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for Rosacea, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Rosacea - Pipeline by Allergan Plc, H1 2016 14
Rosacea - Pipeline by Amorepacific Corporation, H1 2016 15
Rosacea - Pipeline by Delenex Therapeutics AG, H1 2016 16
Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 17
Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2016 18
Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 19
Rosacea - Pipeline by Promius Pharma, LLC, H1 2016 20
Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 21
Rosacea - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Rosacea Therapeutics - Recent Pipeline Updates, H1 2016 51
Rosacea - Dormant Projects, H1 2016 57
Rosacea - Dormant Projects (Contd..1), H1 2016 58
Rosacea - Discontinued Products, H1 2016 59

List of Figures
Number of Products under Development for Rosacea, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Top 10 Targets, H1 2016 24
Number of Products by Stage and Top 10 Targets, H1 2016 24
Number of Products by Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Types, H1 2016 30

Summary of Source & Methodology


Global Markets Direct follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to

Download additional documents & original sources used by researcher/publisher to support the report data

Download Documents
No documents available for download

Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.

Quality Score : 5
Content 5
Reputation 5
Sources 5
Presentation 5
Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.